DFDA

AREDS2 Formula Supplements

Treatment for Macular Degeneration

Typical Dosage: Vitamin C 500 mg, Vitamin E 400 IU, Zinc 80 mg, Copper 2 mg, Lutein 10 mg, Zeaxanthin 2 mg, daily

Effectiveness
30%
Safety Score
90%
Clinical Trials
1
Participants
30K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
90
DangerousModerateSafe
Treatment Details
Dosage Range
Vitamin C 500 mg, Vitamin E 400 IU, Zinc 80 mg, Copper 2 mg, Lutein 10 mg, Zeaxanthin 2 mg, daily
Time to Effect
5+ years
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$400
Monitoring:$500
Side Effect Mgmt:$15
Total Annual:$915
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$1,000/QALY
QALYs Gained
0.03
AREDS2 Formula Supplements Outcomes

for Macular Degeneration

Efficacy Outcomes
Overall Effectiveness
+30%
Common Side Effects
Upset stomach/diarrhea
+5%
Yellowing of skin (harmless)
+1%

Sources:

areds.org
nih.gov
brightfocus.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
1 completed trial for AREDS2 Formula Supplements in Macular Degeneration

Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD

NCT01819415COMPLETEDNA
View Study
40 participants
INTERVENTIONAL
Montreal, Canada
Started: Feb 1, 2011